The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

January - March 2010, Volume 6, Issue 1
Endocrine Care

Ordu S, Gungor A, Yuksel H, Alemdar R, Ozhan H, Yazici M, Albayrak S

The impact of pioglitazone therapy on glycemic control, blood pressure and inflammatory markers in patients with diabetes mellitus

Acta Endo (Buc) 2010, 6 (1): 73-82
doi: 10.4183/aeb.2010.73

Aim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients.\r\nPatients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive Creactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison.\r\nResults. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (?6.5) vs 4(?3.1); p<0.0001]. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (?0.39) vs 0.61 (?0.44); p=0.85].\r\nConclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.

Keywords: Asymmetric dimethylarginine (ADMA), diabetes mellitus, high-sensitive C-reactive protein, homocysteine, insulin resistance, pioglitazone

Correspondence: Serkan Ordu MD, Duzce University D?zce Medical School Department of Cardiology, D?zce Turkey, Tel: 090-533 393 94 46 Fax: +90 380 542 13 87\r\nE-mail: